Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**

Free
AGORACOM NEWS FLASH

AGORACOM Welcomes Back Grizzly Discoveries (GZD: TSX-V)

World class gold and base metal deposits in British Columbia; and diamonds in Alberta $GZD.ca

  • More than 9 million oz Au produced or as resources in a radius of less than 70KM to Greenwood project
  • Holds, or has an interest in, metallic and industrial mineral permits for potash totaling more than 364,000 acres along the Alberta-Saskatchewan border
  • Drillholes with up to 31.1% K2O from assays on recent drill program
  • Portions of Greenwood Project being explored by Kinross through option agreement

Gzdnew

Hub On AGORACOM / Learn More!

-----------------------------------------------------

BREAKING NEWS OUT OF 2 AGORACOM CLIENTS

Namaste Announces Signing of MOU With Marijuana.Ca

  • Entered MOU with Marijuana.Ca, operator of www.marijuana.ca
  • Signing of MOU represents further achievement of the Company’s objective to increase site traffic and develop customer data in the Canadian market
  • Also coincides with the upcoming launch of www.everyonedoesit.ca, which the Company will use to further expand its position in the Canadian market

 

Nlogo

Hub On AGORACOM / Read Release

---------------------------------------------------------

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis

  • Announces launch of its Double-Blind Phase I Study
  • Purpose to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

Tbp large

Hub On AGORACOM / Read Release

Message: Resverlogix Announces Voting Results

News Release Issued: Dec 15, 2016 (9:24pm MST)

Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

CALGARY, Dec. 15, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com

1. Fixing the Number of Directors and Election of Directors

By resolution passed by ballot vote, each of the six nominees proposed as a director were elected as directors of the Corporation to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed.  

The voting results for each nominee is set out below:

 

Votes For

Votes Withheld

   Percent For

Percent Withheld

         

Donald J. McCaffrey

19,496,390

70,726

 

99.64

0.36

Norma Biln

19,482,540

84,576

 

99.57

0.43

Shawn Lu

19,513,279

53,837

 

99.72

0.28

Kelly McNeill

19,293,840

273,276

 

98.60

1.40

Dr. Eldon Smith

19,293,129

273,987

 

98.60

1.40

Kenneth Zuerblis

19,517,090

50,026

 

99.74

0.26

 

2. Appointment of Auditors

By resolution passed by show of hands, KPMG LLP, Chartered Accountants, was appointed as auditor of the Corporation to hold office until the next annual general meeting of the Shareholders and to authorize the Board to fix the auditor's remuneration.

 

3. Approval of Deferred Share Unit Plan

By resolution passed by ballot vote, the adoption of a Deferred Share Unit Plan of the Corporation (the "DSU Plan"). 

The results of the ballot were as follows:

Votes For:

Percent

Votes Against:

Percent

19,309,076

98.29

336,560

1.71

 

4. Proposed Amendment to Royalty Preferred Shares

By resolution passed by ballot vote, a special resolution was passed to approve certain amendments to the terms of the Royalty Preferred Shares as outlined in the Information Circular.  

The results of the ballot were as follows:

Votes For:

Percent

Votes Against:

Percent

19,451,692

99.01

193,944

0.99

 

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). 

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). 

For further information please visit www.resverlogix.com

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: 
ir@resverlogix.com
Phone: 403-254-9252

 

SOURCE Resverlogix Corp.

Share
New Message
Please login to post a reply